RECRUITINGOBSERVATIONAL
Post Marketing Study on Pluvicto in Korea
A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting
About This Trial
Post marketing study on Pluvicto in Korea
Who May Be Eligible (Plain English)
Inclusion criteria
Study participants eligible for inclusion in this study must meet all of the following criteria:
1. Male adult patient age ≥ 18
2. Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
3. Subject who provided the written willing to sign a consent form prior to the study enrollment
Exclusion criteria
Study participants meeting any of the following criteria are not eligible for inclusion in this study:
1. Subject whose medical record is not accessible
2. Subject who is not willing to provide the willing to sign a consent form
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion criteria
Study participants eligible for inclusion in this study must meet all of the following criteria:
1. Male adult patient age ≥ 18
2. Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
3. Subject who provided the written informed consent prior to the study enrollment
Exclusion criteria
Study participants meeting any of the following criteria are not eligible for inclusion in this study:
1. Subject whose medical record is not accessible
2. Subject who is not willing to provide the informed consent
Treatments Being Tested
OTHER
Lutetium vipivotide tetraxetan
This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement.
Locations (8)
Novartis Investigative Site
Seongnam-si, Gyeonggi-do, South Korea
Novartis Investigative Site
Gyeonggi-do, Korea, South Korea
Novartis Investigative Site
Seoul, Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea